Nothing shocking here: the generic versions of Cozaar® and Hyzaar® are making for a banner year at Teva, per The Motley Fool's Brian Orelli, this morning:
. . . .So far, Teva Pharmaceuticals seems to be doing everything right. The addition of German drugmaker Ratiopharm in the third quarter helped boost sales 20% over the year-ago quarter, but adjusted EPS increased a whopping 46% year over year.
Recent launches of new products -- generic versions of Pfizer's Effexor XR, AstraZeneca's Pulmicort Respules, Shire's Adderall XR, Merck's Hyzaar and Cozaar, and Bayer's Yaz -- helped increase the gross margins. . . .
There are now four FDA approved generic-versions of the two Merck drugs, in the US markets. Thus ends the branded franchise.
No comments:
Post a Comment